Joan L Walker

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Management of atypical and low-grade cervical cytology
    Camille A Falkner
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Cancer J 9:377-81. 2003
  2. ncbi request reprint Endometrial cancer metastatic to infrarenal aortic lymph nodes unrecognized during laparoscopic inframesenteric aortic lymph node dissection
    Ram Eitan
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 93:260-2. 2004
  3. ncbi request reprint Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?
    Scott A Kamelle
    Oklahoma Health Sciences Center, USA
    Gynecol Oncol 94:249-55. 2004
  4. pmc Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study
    Joan L Walker
    University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    J Clin Oncol 30:695-700. 2012
  5. pmc HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer
    Rosemary E Zuna
    Department of Pathology, University of Oklahoma Health Sciences Center, 940 SL Young Blvd, Oklahoma City, Oklahoma, 73104 5042, USA
    Infect Agent Cancer 6:19. 2011
  6. pmc Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2
    Joan L Walker
    University of Oklahoma, Oklahoma City, OK 73190, USA
    J Clin Oncol 27:5331-6. 2009
  7. ncbi request reprint Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS)
    Joan L Walker
    Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA
    Am J Obstet Gynecol 195:341-8. 2006
  8. doi request reprint A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study
    Joan L Walker
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 112:78-84. 2009
  9. ncbi request reprint Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
    Joan L Walker
    Department of Obstetrics and Gynecology, University of Oklahoma, PO Box 26901, Oklahoma City, OK 73190, USA
    Gynecol Oncol 100:27-32. 2006
  10. doi request reprint Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Gynecol Oncol 112:337-41. 2009

Detail Information

Publications53

  1. ncbi request reprint Management of atypical and low-grade cervical cytology
    Camille A Falkner
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Cancer J 9:377-81. 2003
    ..with cytology in the screening of women for cervical neoplasia adds a new dilemma to patient management: What should we do with women who are positive for high-risk human papillomavirus DNA but have negative cervical cytologic results?..
  2. ncbi request reprint Endometrial cancer metastatic to infrarenal aortic lymph nodes unrecognized during laparoscopic inframesenteric aortic lymph node dissection
    Ram Eitan
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 93:260-2. 2004
    ..The procedure can be performed either abdominally or laparoscopically. It is unclear, however, as to whether infrarenal aortic nodal sampling above the IMA should be routinely performed...
  3. ncbi request reprint Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?
    Scott A Kamelle
    Oklahoma Health Sciences Center, USA
    Gynecol Oncol 94:249-55. 2004
    ..To evaluate how the independent predictors of recurrence for stage IB2 cervical cancers treated with up-front radical hysterectomy apply to established risk models...
  4. pmc Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study
    Joan L Walker
    University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    J Clin Oncol 30:695-700. 2012
    ..The primary objective was to establish noninferiority of laparoscopy compared with laparotomy for recurrence after surgical staging of uterine cancer...
  5. pmc HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer
    Rosemary E Zuna
    Department of Pathology, University of Oklahoma Health Sciences Center, 940 SL Young Blvd, Oklahoma City, Oklahoma, 73104 5042, USA
    Infect Agent Cancer 6:19. 2011
    ..abstract:..
  6. pmc Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2
    Joan L Walker
    University of Oklahoma, Oklahoma City, OK 73190, USA
    J Clin Oncol 27:5331-6. 2009
    ..The objective was to compare laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer...
  7. ncbi request reprint Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS)
    Joan L Walker
    Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA
    Am J Obstet Gynecol 195:341-8. 2006
    ..Using data from the ASCUS-LSIL Triage Study (ALTS) to inform clinical management, we calculated the absolute risk for developing CIN3 within 2 years of referral to an enrollment colposcopy...
  8. doi request reprint A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study
    Joan L Walker
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 112:78-84. 2009
    ..To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with extended field irradiation in women with cervical cancer metastatic to the para-aortic nodes...
  9. ncbi request reprint Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
    Joan L Walker
    Department of Obstetrics and Gynecology, University of Oklahoma, PO Box 26901, Oklahoma City, OK 73190, USA
    Gynecol Oncol 100:27-32. 2006
    ..To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully complete six cycles of IP chemotherapy...
  10. doi request reprint Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Gynecol Oncol 112:337-41. 2009
    ..The objective of this study is to evaluate overall survival (OS) and progression-free survival (PFS) in patients with advanced EC compared to a cohort of patients with OC matched for age and residual disease...
  11. doi request reprint Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study
    Lisa M Landrum
    University of Oklahoma Health Sciences Center, Section of GYN Oncology, Oklahoma City, OK 73104, USA
    Gynecol Oncol 130:12-8. 2013
    ..To determine prognostic factors for survival in ovarian cancer patients treated with intraperitoneal (IP) chemotherapy using ancillary data from cooperative group clinical trials...
  12. doi request reprint A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
    Natalie Gould
    Division of Gynecologic Oncology, Women s Cancer Center of Nevada, Las Vegas, NV 89169, USA
    Gynecol Oncol 127:506-10. 2012
    ....
  13. pmc A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncol
    Natalie Gould
    Division of Gynecologic Oncology, Women s Cancer Center of Nevada, Las Vegas, NV 89169, USA
    Gynecol Oncol 125:54-8. 2012
    ....
  14. ncbi request reprint Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates
    Lisa M Landrum
    Section of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, P O Box 26901, WP 2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 108:342-7. 2008
    ..The purpose of this study was to review the completion rate of patients receiving i.p. chemotherapy as first line treatment at a single institution and determine what factors prohibit completion of therapy...
  15. doi request reprint Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Boulevard, Oklahoma City, OK, USA
    Gynecol Oncol 108:466-71. 2008
    ..To examine surgico-pathologic outcomes following extraperitoneal para-aortic lymph node dissection (EPLND) via pfannenstiel compared to paramedian incision prior to radiation in patients with cervical cancer...
  16. doi request reprint Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73103, USA
    Gynecol Oncol 110:133-9. 2008
    ..Optimal management for very elderly women (>80) is unclear. This study sought to review the experience with treating ovarian cancer in this population...
  17. ncbi request reprint Carcinosarcoma of the ovary-a case series
    Teresa L Rutledge
    University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Gynecol Oncol 100:128-32. 2006
    ..To evaluate our experience with ovarian carcinosarcoma and identify prognostic factors...
  18. ncbi request reprint Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone
    Todd D Tillmanns
    Department of Obstetrics and Gynecology, University of Tennessee at Memphis, 854 Jefferson Ave, Room E 102, Memphis, TN 38163, USA
    Gynecol Oncol 100:379-84. 2006
    ..A LEEP-Cone may not be necessary for all patients with traditional cone indications. This study defines populations where a single pass technique with the LEEP is appropriate...
  19. ncbi request reprint Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, PO Box 26901, Williams Pavilion 2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 108:584-90. 2008
    ....
  20. ncbi request reprint Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Oklahoma University Health Sciences Center, PO Box 26901, WP2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 106:521-5. 2007
    ..The purpose of this study is to reassess these risk groups in patients treated in an era of contemporary management...
  21. doi request reprint Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 112:134-41. 2009
    ..To determine the maximum tolerated dose (MTD) and feasibility of weekly cisplatin and paclitaxel chemotherapy administered concurrently with whole abdominal radiation therapy (WART) in women with high-risk endometrial cancer...
  22. doi request reprint Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
    Lisa M Landrum
    University of Oklahoma Health Sciences Center, Section of Gynecology Oncology, Oklahoma City, OK 73190, USA
    Gynecol Oncol 122:527-31. 2011
    ..CONCLUSIONS.: Although only 52% of patients were able to complete 6 cycles of cisplatin-based IP chemotherapy, significant reductions in cisplatin-related metabolic toxicity and catheter-related complications were noted...
  23. ncbi request reprint Role of laparoscopic surgery in the management of endometrial cancer
    Meaghan Tenney
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
    J Natl Compr Canc Netw 7:559-67. 2009
    ..This article documents how laparoscopic surgery satisfies the needs of individual patients and surgeons treating this disease...
  24. pmc Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Am J Obstet Gynecol 197:503.e1-6. 2007
    ....
  25. ncbi request reprint Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group
    Paul A DiSilvestro
    Program in Womens Oncology, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905, and Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City 73190, USA
    Gynecol Oncol 103:1038-42. 2006
    ..To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with whole pelvic irradiation in women with locally advanced cervical cancer...
  26. doi request reprint Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?
    Kathleen N Moore
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
    Cancer 115:1472-80. 2009
    ..In the current study, chemotherapy-related toxicity data were evaluated between patients aged > or = 80 years and those aged < 80 years...
  27. pmc Tubal ligation frequency in Oklahoma women with cervical cancer
    Cara A Mathews
    Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Gynecol Oncol 127:278-82. 2012
    ..Infrequent Pap screening is an important risk factor for cervical cancer. We studied the association between contraceptive methods, screening frequency, and cancer...
  28. ncbi request reprint Pathologic findings and outcomes for octogenarians presenting with uterine malignancy
    Kathleen N Moore
    University of Oklahoma Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73103, USA
    Gynecol Oncol 106:572-8. 2007
    ..We evaluated prognostic, demographic and outcome data for patients>80 years old with uterine cancer (UC)...
  29. doi request reprint Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors
    Lisa M Landrum
    Section of Gynecology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA Electronic address
    Gynecol Oncol 132:50-4. 2014
    ....
  30. ncbi request reprint Impact of individual physicians on enrollment of patients into clinical trials
    Robert S Mannel
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, U S A
    Am J Clin Oncol 26:171-3. 2003
    ..This study shows that availability of patients, patient variances, support staff, and institutional commitment are secondary to individual physician factors in determining successful enrollment of patients onto clinical trials...
  31. ncbi request reprint Outpatient implantation of a central venous access system in gynecologic oncology patients
    Jane Shen-Gunther
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, USA
    J Reprod Med 48:875-81. 2003
    ..To determine the feasibility, accuracy, complications and cost of implantation of the PORT-A-CATH II Fluoro-Free venous access system (SIMS Deltec Inc., St. Paul, Minnesota) in the procedure room setting...
  32. ncbi request reprint A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
    Teresa L Rutledge
    University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Gynecol Oncol 95:70-6. 2004
    ..To compare stages IB1 and IB2 cervical cancers treated with radical hysterectomy (RH) and to define predictors of nodal status and recurrence...
  33. doi request reprint Cervical dysplasia among women over 35 years of age
    Kathleen N Moore
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Am J Obstet Gynecol 199:471.e1-5. 2008
    ..The objective of the study was to review the cytologic and histopathologic features among women 35 years of age or older with cervical dysplasia...
  34. ncbi request reprint Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging
    Nina A Mayr
    Radiation Oncology Center, Department of Radiology, Oklahoma University Health Sciences Center, Oklahoma City, OK 73190, USA
    Int J Radiat Oncol Biol Phys 52:14-22. 2002
    ....
  35. ncbi request reprint Laparoscopic pelvic and paraaortic lymph node dissection in the obese
    Dennis R Scribner
    Division of Gynecologic Oncology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73190, USA
    Gynecol Oncol 84:426-30. 2002
    ..The aim of this study was to determine the utility of laparoscopic pelvic and paraaortic lymph node dissection in obese women...
  36. doi request reprint Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals
    James R Hocker
    Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104, USA
    Cancer Invest 30:189-97. 2012
    ..These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease...
  37. ncbi request reprint Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies
    Michael A Gold
    University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Gynecol Oncol 90:325-30. 2003
    ..To determine if amifostine could reduce the hematologic toxicity associated with topotecan...
  38. ncbi request reprint Can frequency and severity of symptoms predict the presence of ovarian cancer?
    Kathleen N Moore
    University of Oklahoma, HSC, Oklahoma City, OK 73104, USA
    Nat Clin Pract Oncol 1:72-3. 2004
  39. doi request reprint Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer
    Catherine Lhomme
    Institut Gustave Roussy, Service de Gynecologie, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 26:2674-82. 2008
    ..To compare the safety and efficacy of carboplatin and paclitaxel administered with or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with advanced ovarian or primary peritoneal cancer...
  40. ncbi request reprint Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods
    Sophia S Wang
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute NIH, 6120 Executive Boulevard, EPS MSC 7234, Bethesda, MD 20892 7234, USA
    Cancer Epidemiol Biomarkers Prev 14:2665-8. 2005
    ..We conclude that the clear discrimination of cervical cancer risk provided by multiple test modalities is consistent with our understanding of cervical etiology related to HPV natural history...
  41. ncbi request reprint Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
    Int J Cancer 117:1007-12. 2005
    ....
  42. ncbi request reprint Ligation of an anatomic variant of renal vasculature during laparoscopic periaortic lymph node dissection: a cause of postoperative renal infarction
    Ram Eitan
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 91:416-20. 2003
    ..Minimally invasive surgical techniques are becoming more sophisticated as complex procedures are being incorporated into gynecologic oncology in routine and investigative settings...
  43. ncbi request reprint Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Baltimore, USA
    N Engl J Med 354:34-43. 2006
    ..The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer...
  44. ncbi request reprint Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study
    Jeffrey Bell
    Ohio State University and Division of Gynecologic Oncology, Riverside Methodist Hospital Columbus Cancer Council, Columbus, OH 43214, USA
    Gynecol Oncol 102:432-9. 2006
    ....
  45. ncbi request reprint Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer
    Christian Marth
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    Cancer 109:645-9. 2007
  46. ncbi request reprint Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study
    Lari B Wenzel
    College of Medicine, University of California at Irvine, Irvine, CA, USA
    J Clin Oncol 25:437-43. 2007
    ..The purpose of this report is to comprehensively evaluate the patient-reported outcomes associated with IP versus IV therapy...
  47. ncbi request reprint Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients
    John K Chan
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco School of Medicine, University of California, San Francisco Comprehensive Cancer Center, California 94143 1702, USA
    Cancer 109:2454-60. 2007
    ....
  48. ncbi request reprint Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment
    Maurie Markman
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:988-94. 2006
  49. pmc Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study
    Lari Wenzel
    University of California, Irvine, Irvine, CA 92697, USA
    Gynecol Oncol 110:60-4. 2008
    ..To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing abdominal discomfort in patients undergoing treatment for ovarian cancer...
  50. ncbi request reprint Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patterns
    Sophia S Wang
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 7234, USA
    Diagn Mol Pathol 14:59-64. 2005
    ....
  51. ncbi request reprint Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers
    Michele Follen
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2044-51. 2003
    ..Researchers recommended using a transgenic mouse model to test and validate new compounds, initiating vaccine and immunomodulator trials, and developing immunologic surrogate endpoint biomarkers...
  52. doi request reprint A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study
    Jay W Carlson
    Gynecologic Oncology of West Michigan, Grand Rapids, MI 49546, USA
    Gynecol Oncol 110:76-82. 2008
    ..To evaluate VH fibrin sealant's influence on lower extremity lymphedema after inguinal lymphadenectomy in vulvar cancer patients...
  53. ncbi request reprint Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels
    Philip E Castle
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20892 7234, USA
    J Clin Immunol 22:23-7. 2002
    ....